177 related articles for article (PubMed ID: 21282055)
1. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
3. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
6. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
7. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
8. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
[TBL] [Abstract][Full Text] [Related]
12. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
14. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Clark MP; George KM; Bookland RG; Chen J; Laughlin SK; Thakur KD; Lee W; Davis JR; Cabrera EJ; Brugel TA; VanRens JC; Laufersweiler MJ; Maier JA; Sabat MP; Golebiowski A; Easwaran V; Webster ME; De B; Zhang G
Bioorg Med Chem Lett; 2007 Mar; 17(5):1250-3. PubMed ID: 17189692
[TBL] [Abstract][Full Text] [Related]
15. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
[TBL] [Abstract][Full Text] [Related]
16. Simplified staurosporine analogs as potent JAK3 inhibitors.
Yang SM; Malaviya R; Wilson LJ; Argentieri R; Chen X; Yang C; Wang B; Cavender D; Murray WV
Bioorg Med Chem Lett; 2007 Jan; 17(2):326-31. PubMed ID: 17088059
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
Hunt JT; Mitt T; Borzilleri R; Gullo-Brown J; Fargnoli J; Fink B; Han WC; Mortillo S; Vite G; Wautlet B; Wong T; Yu C; Zheng X; Bhide R
J Med Chem; 2004 Jul; 47(16):4054-9. PubMed ID: 15267243
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Tang F; Wang J; Liu F
Bioorg Med Chem; 2017 Jan; 25(1):75-83. PubMed ID: 27771180
[TBL] [Abstract][Full Text] [Related]
20. Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
Miller MS; Pinson JA; Zheng Z; Jennings IG; Thompson PE
Bioorg Med Chem Lett; 2013 Feb; 23(3):802-5. PubMed ID: 23265896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
